Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Вариант течения холангиокарциномы: обзор литературы и собственное клиническое наблюдение
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Статья посвящена обзору литературных данных и описанию собственного клинического наблюдения редкой формы холангиокарциномы с локализацией в области бифуркации общего печеночного протока – опухоли Клатскина. Описанное клиническое наблюдение иллюстрирует трудности дифференциальной диагностики и верификации диагноза в рамках рассматриваемой патологии у пациента, поступившего в многопрофильный стационар с выраженными проявлениями холестатического синдрома.
Ключевые слова: опухоль Клатскина, холангиокарцинома, желтуха, холестаз, дифференциальная диагностика, ЭРХПГ.
Ключевые слова: опухоль Клатскина, холангиокарцинома, желтуха, холестаз, дифференциальная диагностика, ЭРХПГ.
________________________________________________
The authors review the data available in the literature on and describe their own clinical observation of Klatskin tumor, a rare form of cholangiocarcinoma located at the bifurcation of the common hepatic duct. The described clinical case illustrates difficulties in making a differential diagnosis and verifying its diagnosis within the disease in question in a patient admitted to a multidisciplinary hospital because of the marked manifestations of cholestatic syndrome.
Key words: Klatskin tumor, cholangiocarcinoma, jaundice, cholestasis, differential diagnosis, endoscopic retrograde cholangiopancreatography.
Полный текст
Список литературы
1. De Groen PC, Gores GJ, LaRusso NF et al. Biliary tract cancers. NEJM 1999; 341 (18): 1368–78.
2. Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J Gastroenterol 2009; 15 (34): 4240–62.
3. Patel T. Cholangiocarcinoma. Nat Cli. Pract Gastroenterol Hepatol 2006; 3: 33–42.
4. Kuang D, Wang G. Hilar cholangiocarcinoma: Pathology and tumor biology. Front Med China 2010; 4: 371–7.
5. Klatskin G. Adenocarcinoma of the hepatic ducts at its bifurcation within the porta hepatis. Am J Med 1965; 38: 241–56.
6. Somer L, Andrejić B, Milošević P. Origin and pathological characteristics of Klatskin tumor: a case report and literature review. Pol J Pathol 2012; 63 (1): 65–70.
7. Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obset 1975; 140: (170–8).
8. Вишневский В.А., Тарасюк Т.И. Диагностика и хирургическое лечение рака проксимальных отделов внепеченочных желчных протоков (опухоль Клатскина). Практ. онкология. 2004; 5 (2): 126–34.
9. Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale's Pharmacology. Elsevier Churchill Livingstone 2007.
10. Tsuzuki T, Ogata Y, Lida S et al. Carcinoma of the bifurcation of the hepatic ductus. Arch Surg 1987; 205 (2): 111–8.
11. Ouchi K, Matsuno S, Sato T. Long-term survival in carcinoma of biliary tract. Arch Surg 2007; 124: 248–52.
12. Dawson JL, Heaton ND. Carcinoma of the biliary tree and gallbladder. Surgery Inter Edit 2006; 17: 84–8.
13. Bamrungphon W, Prempracha N, Bunchu N et al. A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett 2007; 247: 301–8.
14. Кунцевич Г.И. Ультразвуковая диагностика в абдоминальной и сосудистой хирургии. Минск, 1999.
15. Slattery JM, Sahani DV. What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma? Oncologist 2006; 11: 913–22.
16. Hann LE, Getrajdman GI, Brown KT et al. Hepatic lobar atrophy: association with ipsilateral portal vein obstruction. AJR Am J Roentgenol 1996; 167: 1017–21.
17. Lee HY, Kim SH, Lee JM et al. Preoperative assessment of resectability of hepatic hilar cholangiocarcinoma: combined CT and cholangiography with revised criteria. Radiology 2006; 239: 113–21.
18. Romagnuolo J, Bardou M, Rahme E et al. Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease. Ann Intern Med 2003; 139: 547–57.
19. Chen CY, Shiesh SC, Tsao HC, Lin XZ. The assessment of biliary CA 125, CA 19–9 and CEA in diagnosing cholangiocarcinoma – the influence of sampling time and hepatolithiasis. Hepatogastroenterology 2002; 49: 616–20.
20. Hochwald SN, Burke EC, Jarnagin WR et al. Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg 1999; 134: 261–6.
21. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. National Comprehensive Cancer Network 2011; 1 (1).
22. Федоров В.Д., Вишневский В.А., Кубышкин В.А. и др. Хирургическое лечение рака общего печеночного протока. Кремл. мед. 2000; 2: 13–6.
23. Su CH, Tsay SH, Wu CC et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996; 223: 384–94.
24. Mihalache F, Tantau M, Diaconu B et al. M. Survival and quality of life of cholangiocarcinoma patients: a prospective study over a 4 year period. J Gastrointestin Liver Dis 2010; 9: 285–90.
25. Todoroki T, Kawamoto T, Koike N et al. Radical resection of hilar bile duct carcinoma and predictors of survival. Br J Surg 2000; 87: 306–13.
26. Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol 2005; 16 (Suppl. 2): 93–6.
27. Ustundag Y, Bayraktar Y. Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol 2008; 14 (42): 6458–66.
28. Ortner MA. Photodynamic therapy in cholangiocarcinomas. Best Pract Res Clin Gastroenterol 2004; 18: 147–54.
29. Tomizawa Y, Tian J. Photodynamic therapy for unresectable cholangiocarcinoma. Dig Dis Sci 2012; 57 (2): 274–83.
30. Lau SH, Lau WY. Current therapy of hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2012; 11 (1): 12–7.
2. Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J Gastroenterol 2009; 15 (34): 4240–62.
3. Patel T. Cholangiocarcinoma. Nat Cli. Pract Gastroenterol Hepatol 2006; 3: 33–42.
4. Kuang D, Wang G. Hilar cholangiocarcinoma: Pathology and tumor biology. Front Med China 2010; 4: 371–7.
5. Klatskin G. Adenocarcinoma of the hepatic ducts at its bifurcation within the porta hepatis. Am J Med 1965; 38: 241–56.
6. Somer L, Andrejić B, Milošević P. Origin and pathological characteristics of Klatskin tumor: a case report and literature review. Pol J Pathol 2012; 63 (1): 65–70.
7. Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obset 1975; 140: (170–8).
8. Вишневский В.А., Тарасюк Т.И. Диагностика и хирургическое лечение рака проксимальных отделов внепеченочных желчных протоков (опухоль Клатскина). Практ. онкология. 2004; 5 (2): 126–34.
9. Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale's Pharmacology. Elsevier Churchill Livingstone 2007.
10. Tsuzuki T, Ogata Y, Lida S et al. Carcinoma of the bifurcation of the hepatic ductus. Arch Surg 1987; 205 (2): 111–8.
11. Ouchi K, Matsuno S, Sato T. Long-term survival in carcinoma of biliary tract. Arch Surg 2007; 124: 248–52.
12. Dawson JL, Heaton ND. Carcinoma of the biliary tree and gallbladder. Surgery Inter Edit 2006; 17: 84–8.
13. Bamrungphon W, Prempracha N, Bunchu N et al. A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett 2007; 247: 301–8.
14. Кунцевич Г.И. Ультразвуковая диагностика в абдоминальной и сосудистой хирургии. Минск, 1999.
15. Slattery JM, Sahani DV. What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma? Oncologist 2006; 11: 913–22.
16. Hann LE, Getrajdman GI, Brown KT et al. Hepatic lobar atrophy: association with ipsilateral portal vein obstruction. AJR Am J Roentgenol 1996; 167: 1017–21.
17. Lee HY, Kim SH, Lee JM et al. Preoperative assessment of resectability of hepatic hilar cholangiocarcinoma: combined CT and cholangiography with revised criteria. Radiology 2006; 239: 113–21.
18. Romagnuolo J, Bardou M, Rahme E et al. Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease. Ann Intern Med 2003; 139: 547–57.
19. Chen CY, Shiesh SC, Tsao HC, Lin XZ. The assessment of biliary CA 125, CA 19–9 and CEA in diagnosing cholangiocarcinoma – the influence of sampling time and hepatolithiasis. Hepatogastroenterology 2002; 49: 616–20.
20. Hochwald SN, Burke EC, Jarnagin WR et al. Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg 1999; 134: 261–6.
21. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. National Comprehensive Cancer Network 2011; 1 (1).
22. Федоров В.Д., Вишневский В.А., Кубышкин В.А. и др. Хирургическое лечение рака общего печеночного протока. Кремл. мед. 2000; 2: 13–6.
23. Su CH, Tsay SH, Wu CC et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996; 223: 384–94.
24. Mihalache F, Tantau M, Diaconu B et al. M. Survival and quality of life of cholangiocarcinoma patients: a prospective study over a 4 year period. J Gastrointestin Liver Dis 2010; 9: 285–90.
25. Todoroki T, Kawamoto T, Koike N et al. Radical resection of hilar bile duct carcinoma and predictors of survival. Br J Surg 2000; 87: 306–13.
26. Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol 2005; 16 (Suppl. 2): 93–6.
27. Ustundag Y, Bayraktar Y. Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol 2008; 14 (42): 6458–66.
28. Ortner MA. Photodynamic therapy in cholangiocarcinomas. Best Pract Res Clin Gastroenterol 2004; 18: 147–54.
29. Tomizawa Y, Tian J. Photodynamic therapy for unresectable cholangiocarcinoma. Dig Dis Sci 2012; 57 (2): 274–83.
30. Lau SH, Lau WY. Current therapy of hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2012; 11 (1): 12–7.
Авторы
И.В.Маев1, Д.Т.Дичева1, Д.Н.Андреев1, Т.В.Пенкина2, Ю.С.Сенина1
1 Кафедра пропедевтики внутренних болезней и гастроэнтерологии ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РФ
2 ФКУЗ Главный клинический госпиталь МВД России
1 Кафедра пропедевтики внутренних болезней и гастроэнтерологии ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РФ
2 ФКУЗ Главный клинический госпиталь МВД России
________________________________________________
I.V.Mayev, D.T.Dicheva, D.N.Andreyev, T.V.Penkina, Yu.S.Senina
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.